Twist

A Revolutionary Twist on Takeout and Delivery with New Twist & Crispy™ Containers from Sabert

Retrieved on: 
Dienstag, Juni 4, 2024
Twist, Food quality, Marketing, New product development, Food, Fast food

Independent lab testing conducted by Tentamus North America showed that the Twist & Crispy™ containers keep food hot and crispy for up to 40 minutes without degrading—20% longer than competitive packaging options.

Key Points: 
  • Independent lab testing conducted by Tentamus North America showed that the Twist & Crispy™ containers keep food hot and crispy for up to 40 minutes without degrading—20% longer than competitive packaging options.
  • Twist & Crispy™ containers feature a unique dual-locking lid that allows for two configurations—a vented position enabling airflow to keep food crispy or a sealed option forming a spill-proof barrier to contain saucier menu items.
  • By consolidating vented and non-vented containers into one versatile solution, Twist & Crispy™ containers can keep menu items crispy or spill-proof while streamlining back-of-house operations and inventory."
  • Twist & Crispy™ containers are made in the USA and are available in multiple sizes to accommodate varied menu applications.

Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor

Retrieved on: 
Donnerstag, Juni 6, 2024
Research, Technology, Semiconductor, Genetics, Clinical Trials, Health Technology, Nanotechnology, Biotechnology, Health, Science, Silicon, Neoplasm, Colorectal cancer, Library, Central nervous system, Melanoma, DNA, G protein-coupled receptor, Twist Bioscience, Immunosuppression, Cancer, Environment, Tumor microenvironment, Therapy, PD-1, PLOS, Twist, Antibody, Adenosine, Stomach, Animal, Lymph node metastasis, Doctor of Philosophy, Breast cancer, Vaccine

The study titled, “ Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor ”, was published in the journal PLOS ONE.

Key Points: 
  • The study titled, “ Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor ”, was published in the journal PLOS ONE.
  • A2AR is an emerging immune checkpoint that plays a role in the immunosuppression of the tumor microenvironment.
  • “Using the ability to create large antibody libraries enabling discovery of novel and highly specific therapeutics, Twist has discovered an antibody that blocks A2AR, a promising checkpoint target and demonstrated its activity in preclinical models.
  • The antibody could be further developed as a standalone therapy, bispecific or combination therapy to bring potential therapeutic benefit to patients.”

Twist Bioscience Announces Participation in Department of Commerce Consortium Dedicated to AI Safety

Retrieved on: 
Dienstag, Juni 4, 2024
Health Technology, White House, Federal Government, Security, Technology, Nanotechnology, Oncology, General Health, Public Policy, Government, Genetics, Artificial Intelligence, Biotechnology, Science, Software, Other Science, Research, Health, Twist, Silicon, Twist Bioscience, Safety, DNA, Artificial intelligence, Doctor of Philosophy, AI, Organization, NIST

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the company has joined the U.S. AI Safety Institute Consortium (AISIC), a group established by the Department of Commerce’s National Institute of Standards and Technology (NIST) to support the development and deployment of trustworthy and safe AI.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the company has joined the U.S. AI Safety Institute Consortium (AISIC), a group established by the Department of Commerce’s National Institute of Standards and Technology (NIST) to support the development and deployment of trustworthy and safe AI.
  • “Biosecurity has been a priority for Twist since the inception of the company, and we continue to advance our biosecurity measures with the introduction of new technology and products to keep us at the forefront of biosecurity,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • The consortium also includes state and local governments, as well as non-profits.
  • The consortium will also work with organizations from like-minded nations that have a key role to play in setting interoperable and effective safety around the world.

Oxford Nanopore Technologies Collaborates With Twist Bioscience to Launch Pharmacogenomics Beta Programme and Advance Personalised Medicine

Retrieved on: 
Mittwoch, Mai 22, 2024
Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Other Science, Research, Data Analytics, Software, Genetics, Science, Dark, Oxford Nanopore Technologies, NGS, Doctor of Philosophy, Twist, CYP2D6, Medicine, Twist Bioscience, Gene

Oxford Nanopore Technologies (Oxford Nanopore) today announced the launch of a new Pharmacogenomics (PGx) Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.

Key Points: 
  • Oxford Nanopore Technologies (Oxford Nanopore) today announced the launch of a new Pharmacogenomics (PGx) Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.
  • The beta program aims to increase the diversity of genetic variants evaluated by Oxford Nanopore’s platform.
  • “Our collaboration with Twist Bioscience underscores our commitment to advancing the possibility of personalised medicine through PGx by providing unambiguous genetic results in a single assay,” said Gordon Sanghera, CEO of Oxford Nanopore.
  • “The exceptional uniformity of our sequencer agnostic workflows enables researchers around the world to advance scientific breakthroughs.”
    For more information about the PGx Beta Program and other innovations from Oxford Nanopore Technologies, visit https://nanoporetech.com .

Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications

Retrieved on: 
Montag, Mai 13, 2024
Technology, Research, Genetics, Other Technology, Nanotechnology, Biotechnology, Health, Other Science, Science, CRISPR, DNA, Doctor of Philosophy, Silicon, Twist Bioscience, Protein engineering, Twist, Passenger name record, Fine chemical

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA (dsDNA) up to 500 base pairs in length with no limit on sequence number to enable high throughput screening applications.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA (dsDNA) up to 500 base pairs in length with no limit on sequence number to enable high throughput screening applications.
  • “Using our chemical synthesis platform we are able to directly synthesize Twist Multiplexed Gene Fragments as fragment pools of up to 500 bp in length.
  • By offering Twist's high-quality gene fragments in a pooled format at prices that scale with the number of sequences, Twist is enabling customers to conduct applications that may have been previously unfeasible or cost-prohibitive, facilitating high-throughput screening in a way that is far more accessible to researchers across industry segments,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • Twist Multiplexed Gene Fragments are pools of customizable double-stranded DNA (dsDNA) between 301-500 base pairs in length.

Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 2, 2024
Technology, Biotechnology, Nanotechnology, Chemicals, Plastics, Health, Manufacturing, Pharmaceutical, Other Science, Research, General Health, Genetics, Health Technology, Science, Data Management, Twist, Doctor of Philosophy, Nucleic acid thermodynamics, Net, Genomics, Investment, Exome, Capital, Sequence, PIN, Depreciation, Silicon, Genetic variation, Growth, Twist Bioscience, NGS, Development, Administration, SynBio, Tax, UHT, Adjustment, Telephone, GAAP, Element, Gene, Tobacco

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.
  • Shipped products to 2,253 customers in the second quarter of fiscal 2024, compared to approximately 2,100 customers in the second quarter of fiscal 2023.
  • Shipped approximately 193,000 genes during the second quarter of fiscal 2024, compared with approximately 152,000 genes during the second quarter of fiscal 2023.
  • For the third quarter of fiscal year 2024, Twist provided the following financial guidance:
    For the fourth quarter of fiscal year 2024, Twist provided the following financial guidance:
    1For in vitro diagnostic use.

Barfresh Highlights Many New Wins With its Smoothies in the Education Channel

Retrieved on: 
Freitag, April 26, 2024
Twist, Tropical Smoothie Cafe, Student, Growth, LOS

LOS ANGELES, April 26, 2024 (GLOBE NEWSWIRE) -- Barfresh Food Group Inc. (the “Company” or “Barfresh”) (Nasdaq: BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, has continued to expand its presence within the education channel and announced today a number of recent large wins within the education channel. The Company recently secured seven school co-operatives, serving over 2,200 school locations and approximately 1.5 million students. These new school locations will serve a variety of the Company’s products, including its carton and bottle smoothie products, 5:1 100% juice concentrates and 1:1 bulk easy pour smoothie concentrates.

Key Points: 
  • The Company recently secured seven school co-operatives, serving over 2,200 school locations and approximately 1.5 million students.
  • These new school locations will serve a variety of the Company’s products, including its carton and bottle smoothie products, 5:1 100% juice concentrates and 1:1 bulk easy pour smoothie concentrates.
  • Riccardo Delle Coste, the Company’s Chief Executive Officer, stated, “We are thrilled to announce a number of significant new customer wins within our education channel.
  • These new 2,200 school locations will offer a variety of our products, cementing how important it is for us to offer a diverse lineup of quality, nutritious products to fit the varying needs across the education channel.

Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations

Retrieved on: 
Donnerstag, März 28, 2024
Research, Technology, Semiconductor, Genetics, Nanotechnology, Biotechnology, Hardware, Health, Data Management, Science, Genetic variation, Panel, NHGRI, Twist Bioscience, Twist, WES, Genome, Doctor of Philosophy, Sequence, Production, Exome, Silicon

In order to advance science for all people, researchers need to have tools that enable them to conduct research relevant to people from diverse backgrounds,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • In order to advance science for all people, researchers need to have tools that enable them to conduct research relevant to people from diverse backgrounds,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • “When companies such as Twist utilize our reference standard to create research tools, it facilitates scientists’ study of genetic variation.
  • The Twist Human Pangenome Spike-in Panel targets 2.5 Mb of pangenome variants and can be spiked into the Twist Exome 2.0 to target more than 94% of the novel pangenome variants affecting coding sequences in the exome.
  • If interested in the Human Pangenome Spike-in Panel for the Twist Exome 2.0 panel, please complete the contact form here: https://www.twistbioscience.com/contact

New Tovolo® Mini Ice Cylinders and Trays Offer Easy and Inexpensive Solutions for Creating Trendy Nugget Ice at Home

Retrieved on: 
Donnerstag, März 14, 2024
TWIST, Drink, BPA, Charcoal, Twist, Ice, MSRP, Amazon (company), Mini

1: Mini Ice Cylinders – Squeeze & ReleaseThis whimsical solution is fun to use and satisfyingly addicting! Featuring a compact-sized, squeezable design, the innovative and easy-to-use cylinder makes enough ice to chill more than two drinks--creating 200 mini ice cubes per batch. Simply squeeze to pop the ice free.    

Key Points: 
  • Tovolo®, a leader in go-to kitchen innovations, is changing the game by bringing this trendy ice option to consumer kitchens with two innovative new Mini Ice products.
  • Tovolo® is changing the game by bringing popular nugget ice to consumer kitchens with innovative new Mini Ice products.
  • The Tovolo® Mini Ice products are designed to make the popular nugget-style ice easily and affordably.
  • MSRP $17.99
    The unique diamond-shaped orientation of the ice on the Twist & Release Mini Ice Trays makes popping the ice out simple.

Barfresh Provides Fourth Quarter and Full Year 2023 Results and Business Update

Retrieved on: 
Donnerstag, Februar 29, 2024
Engineering, Twist, Marketing, Growth, Adjustment, GAAP, COVID, Research, Video game

LOS ANGELES, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Barfresh Food Group Inc. (the “Company” or “Barfresh”) (Nasdaq: BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, is providing a business update for the full year ended December 31, 2023.

Key Points: 
  • Gross margins for the fourth quarter of 2023 were 33%, compared to 36% for the fourth quarter of fiscal year 2022.
  • Net loss for the fourth quarter of 2023 was $701,000, as compared to a loss of $1.9 million in the fourth quarter of 2022.
  • Selling, marketing and distribution for the fourth quarter of 2023 was $624,000, compared to $625,000 in the fourth quarter of 2022.
  • G&A expenses for the fourth quarter of 2023 decreased 31% to $629,000 compared to $912,000 in the fourth quarter of 2022.